Clinical Trial Update: Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study of KITE-197 for relapsed or refractory diffuse large B-cell lymphoma is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• KITE-197

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING